中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2008年
12期
926-929
,共4页
詹晓凯%孙永琨%张雯%王金万
詹曉凱%孫永琨%張雯%王金萬
첨효개%손영곤%장문%왕금만
小细胞癌%食管肿瘤%临床特征%预后
小細胞癌%食管腫瘤%臨床特徵%預後
소세포암%식관종류%림상특정%예후
Small cell carcinoma%Esophageal neoplasms%Clinical characteristics%Prognosis
目的 探讨原发食管小细胞癌的临床特点、治疗方法和预后.方法 收集和分析81例原发食管小细胞癌的临床和随访资料.结果 81例患者中,男58例,女23例,年龄35～82岁,中位年龄60岁.75例患者有分期资料,其中局限期52例,广泛期23例.原发于食管中段42例,食管下段29例,食管上段9例.单纯小细胞癌77例,混合型4例.81例患者中,20例仅接受了1种手段治疗,其中11例接受手术治疗,6例接受化疗,3例接受放疗;61例接受了1种以上方式的综合治疗,其中以术后化疗居多(30例).81例患者生存时间为2～76个月,中位生存时间为13.5个月.1、3、5年生存率分别为55.6%、6.2%和2.5%.局限期患者中位生存时间为15个月,1、3、5年生存率分别为69.2%、7.3%和3.6%;广泛期患者中位生存时间为6个月,1、3年生存率分别为25.2%和0.多因素Cox比例风险模型回归分析显示,临床分期、体能状况、治疗方式和治疗模式是原发食管小细胞癌患者预后的独立影响因素.结论 原发食管小细胞癌是一种少见且恶性度极高的肿瘤,临床分期、患者的体能状况是影响预后的重要因素,采用合理的治疗是提高患者生存的主要措施.
目的 探討原髮食管小細胞癌的臨床特點、治療方法和預後.方法 收集和分析81例原髮食管小細胞癌的臨床和隨訪資料.結果 81例患者中,男58例,女23例,年齡35～82歲,中位年齡60歲.75例患者有分期資料,其中跼限期52例,廣汎期23例.原髮于食管中段42例,食管下段29例,食管上段9例.單純小細胞癌77例,混閤型4例.81例患者中,20例僅接受瞭1種手段治療,其中11例接受手術治療,6例接受化療,3例接受放療;61例接受瞭1種以上方式的綜閤治療,其中以術後化療居多(30例).81例患者生存時間為2～76箇月,中位生存時間為13.5箇月.1、3、5年生存率分彆為55.6%、6.2%和2.5%.跼限期患者中位生存時間為15箇月,1、3、5年生存率分彆為69.2%、7.3%和3.6%;廣汎期患者中位生存時間為6箇月,1、3年生存率分彆為25.2%和0.多因素Cox比例風險模型迴歸分析顯示,臨床分期、體能狀況、治療方式和治療模式是原髮食管小細胞癌患者預後的獨立影響因素.結論 原髮食管小細胞癌是一種少見且噁性度極高的腫瘤,臨床分期、患者的體能狀況是影響預後的重要因素,採用閤理的治療是提高患者生存的主要措施.
목적 탐토원발식관소세포암적림상특점、치료방법화예후.방법 수집화분석81례원발식관소세포암적림상화수방자료.결과 81례환자중,남58례,녀23례,년령35～82세,중위년령60세.75례환자유분기자료,기중국한기52례,엄범기23례.원발우식관중단42례,식관하단29례,식관상단9례.단순소세포암77례,혼합형4례.81례환자중,20례부접수료1충수단치료,기중11례접수수술치료,6례접수화료,3례접수방료;61례접수료1충이상방식적종합치료,기중이술후화료거다(30례).81례환자생존시간위2～76개월,중위생존시간위13.5개월.1、3、5년생존솔분별위55.6%、6.2%화2.5%.국한기환자중위생존시간위15개월,1、3、5년생존솔분별위69.2%、7.3%화3.6%;엄범기환자중위생존시간위6개월,1、3년생존솔분별위25.2%화0.다인소Cox비례풍험모형회귀분석현시,림상분기、체능상황、치료방식화치료모식시원발식관소세포암환자예후적독립영향인소.결론 원발식관소세포암시일충소견차악성도겁고적종류,림상분기、환자적체능상황시영향예후적중요인소,채용합리적치료시제고환자생존적주요조시.
Objective To evaluate the clinical characteristics, treatment and prognostic factors in patients with primary small cell carcinoma (SmCC) of the esophagus. Methods Eighty-one esophageal SmCC patients were treated from 1999 to 2007 in our department, and their clinical data were retrospectively reviewed. Results Of the 81 patients, 52 (64.2% ) were in limited stage (LS) and 23 (28.4%) in extensive stage (ES). The 1-, 3- and 5-year survival rates were 55.6%, 6.2% and 2.5%, respectively, with a median survival time of 13.5 months for the whole group; 69.2%, 7.3% and 3.6%, respectively, with a median survival time of 15 months for the LS group; while only 25.2%, 0 and 0, respectively, with a median survival time of 6 months for the ES group. Multivariate analysis showed that disease stage, performance status, muhidiaciplinary comprehensive therapy and mode of treatment were independent prognostic factors. Conclusion Esophageal small cell carcinoma is a rare but highly aggressive malignant tumor. Disease stage and performance status are important prognostic factors. Appropriate treatment may play a key role in improving the survival of the patients.
